IBCORI Results
IBCORI over time
The Ibcori project focuses on the characterization of one or more biological entities with broad protective efficacy against influenza A virus (IAV) infection. The key innovation is a nanobody-based protective molecule designed for passive inhalable immunotherapy, targeting the elderly population during the annual flu season. Additionally, this biological agent holds promise for deployment during pandemic emergencies to help control outbreaks.
The project has now surpassed its halfway mark, and although ongoing, it has already yielded several promising outcomes:
Discovery of Unique Candidates: Nanobodies (NBs) capable of neutralizing both group 1 and group 2 Influenza A Viruses (IAVs) have been identified, marking a novel achievement in the field.
In-depth Characterization: The identified candidates are undergoing comprehensive characterization, demonstrating significant potential through in vitro antiviral and biophysical activity assays, as well as in mouse challenge studies.
Advanced Development: The project has successfully generated and produced these candidates, including NB humanization and Fc fusion constructs, using transiently transfected cell models (CHO and HEK293 cells).
Ongoing Cell Line Development: The project continues to refine and advance an in-house, free-to-operate CHO cell line to support further development.
Patent Strategy: A robust patent strategy is being developed to protect the nanobodies based on their sequence, as well as their in vitro and in vivo anti-IAV neutralizing potency. Additionally, consideration is being given to the specific epitopes within the hemagglutinin (HA) that these nanobodies target.